SHANGHAI, Jan. 12, 2026 /PRNewswire/ — WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data, with revenue from Continuing Operations growing by approximately 21.4% year-over-year.
Important notices of the announcement are as follows:
WuXi AppTec maintains a laser focus on its unique, integrated and end-to-end CRDMO business model. In response to ongoing customer demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. This strategy is driving sustained long-term business growth, delivering highly efficient and exceptional services to customers, and helping to bring groundbreaking therapies to patients worldwide.
- Total revenue for the full year of 2025 is expected to be approximately RMB45.46 billion, representing a year-over-year increase of approximately 15.8%, with revenue from Continuing Operations …